Research
Hormonal
Tirzepatide use is associated with specific adverse events in females, including starvation ketoacidosis, menstrual disorders, and postmenopausal hemorrhage.
Women taking tirzepatide should be aware of potential changes in their menstrual cycle, including irregular bleeding or postmenopausal hemorrhage. If you experience these changes, consult your healthcare provider.
ModerateSupportsMEDIUM confidence
Females are more prone to starvation ketoacidosis and incorrect injection sites... postmenopausal haemorrhage (n = 46, ROR: 9.92), menstrual disorder (n = 37, ROR: 2.85)... implying regulatory interference on sex hormones.
Why this rating
Based on FAERS data; high ROR indicates a strong signal, but spontaneous reporting limits causal certainty.
Source
Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method
Saisai Gu · Drug Healthcare and Patient Safety · 2026
DOI 10.2147/dhps.s556918
cohort · n=67305Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide use is associated with a high frequency of early-onset adverse events, with a median time-to-onset of approximately 6.4 days, driven by gastrointestinal disturbances, injection site reactions, and metabolic effects.Moderate
- Tirzepatide use is associated with specific adverse events in males, including sleep disorders, delayed gastric emptying, and medullary thyroid cancer.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →